KLINIKKEN VED SØERNE ApS

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
Loading...

Loading...

Loading...

Loading...

Loading...

Loading...

Loading...

Bankruptcy Risk 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  8.8% 12.1% 10.7% 10.7% 7.9%  
Credit score (0-100)  29 19 21 22 30  
Credit rating  BB BB BB BB BB  
Credit limit (kDKK)  0.0 0.0 0.0 0.0 0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  527 428 563 537 0  
Gross profit  84.7 63.6 -24.6 -18.9 23.1  
EBITDA  3.3 -3.8 -24.6 -27.0 23.1  
EBIT  3.3 -3.8 -31.3 -35.6 14.6  
Pre-tax profit (PTP)  1.2 -3.9 -31.5 -35.6 24.6  
Net earnings  0.1 -4.3 -31.5 -35.6 24.6  
Pre-tax profit without non-rec. items  1.2 -3.9 -31.5 -35.6 24.6  

 
See the entire income statement

Balance sheet (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Tangible assets total  0.0 0.0 22.0 13.4 4.9  
Shareholders equity total  154 149 118 82.3 157  
Interest-bearing liabilities  0.0 0.0 90.1 128 84.3  
Balance sheet total (assets)  216 207 214 210 252  

Net Debt  -12.8 -26.4 75.2 126 42.9  
 
See the entire balance sheet

Volume 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  527 428 563 537 0  
Net sales growth  -3.3% -18.8% 31.6% -4.6% -100.0%  
Gross profit  84.7 63.6 -24.6 -18.9 23.1  
Gross profit growth  -32.2% -24.9% 0.0% 22.9% 0.0%  
Employees  0 0 0 0 0  
Employee growth %  0.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  216 207 214 210 252  
Balance sheet change%  8.1% -4.3% 3.6% -1.7% 19.9%  
Added value  3.3 -3.8 -24.6 -28.8 23.1  
Added value %  0.6% -0.9% -4.4% -5.4% 0.0%  
Investments  -3 -3 12 -17 -17  

Net sales trend  -1.0 -2.0 1.0 -1.0 -2.0  
EBIT trend  3.0 -1.0 -2.0 -3.0 1.0  

Profitability 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
EBITDA %  0.6% -0.9% -4.4% -5.0% 0.0%  
EBIT %  0.6% -0.9% -5.6% -6.6% 0.0%  
EBIT to gross profit (%)  3.9% -5.9% 127.5% 187.9% 63.0%  
Net Earnings %  0.0% -1.0% -5.6% -6.6% 0.0%  
Profit before depreciation and extraordinary items %  0.0% -1.0% -4.4% -5.0% 0.0%  
Pre tax profit less extraordinaries %  0.2% -0.9% -5.6% -6.6% 0.0%  
ROA %  1.6% -1.8% -14.9% -16.8% 10.6%  
ROI %  2.2% -2.4% -17.4% -17.0% 10.9%  
ROE %  0.1% -2.8% -23.6% -35.6% 20.6%  

Solidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Equity ratio %  71.2% 72.4% 55.1% 39.1% 62.2%  
Relative indebtedness %  11.3% 12.7% 17.1% 23.8% 0.0%  
Relative net indebtedness %  8.9% 6.6% 14.4% 23.6% 0.0%  
Net int. bear. debt to EBITDA, %  -384.1% 701.7% -306.3% -468.3% 185.6%  
Gearing %  0.0% 0.0% 76.4% 155.2% 53.7%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 0.0% 0.4% 0.1% 0.0%  

Liquidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Quick Ratio  0.4 0.5 2.0 1.5 2.6  
Current Ratio  0.4 0.5 2.0 1.5 2.6  
Cash and cash equivalent  12.8 26.4 14.9 1.2 41.3  

Capital use efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Trade debtors turnover (days)  4.1 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 -0.0 -0.0 0.0  
Current assets / Net sales %  4.0% 6.2% 34.1% 36.7% 0.0%  
Net working capital  -38.4 -28.1 95.9 68.9 152.0  
Net working capital %  -7.3% -6.6% 17.1% 12.8% 0.0%  

Employee efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Net sales / employee  0 0 0 0 0  
Added value / employee  0 0 0 0 0  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 0 0 0  
EBIT / employee  0 0 0 0 0  
Net earnings / employee  0 0 0 0 0